carbon nanoparticles
PreclinicalSmall molecule
carbon nanoparticles is one of 48 small molecule programs targeting Thyroid Cancer. It is currently in Preclinical.
1
Indications
3
Total Trials
0
Active Trials
47
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
65 competitors in Thyroid Cancer
#DrugCompanyPhaseTrials
1Lenvima
EisaiApproved
Keytruda
Merck & Co.Approved
Vitrakvi
BayerApproved
Retevmo
Eli LillyApproved
Gemzar
Johnson & JohnsonApproved
Nexavar
BayerPhase 3
Mekinist
NovartisPhase 3
Gavreto
RRigel Pharmaceuticals
Approved
Farydak
SSecuraBio
Approved
Torisel
PPrism Pharmaceuticals
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Gastric Cancer1 trial
Thyroid Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for carbon nanoparticles. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details